Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.187
Neutral
RSI(14)
51.436
Neutral
STOCH(KDJ)(9,3,3)
65.542
Neutral
ATR(14)
2.186
Low Volatility
CCI(14)
-6.941
Neutral
Williams %R
43.437
Buy
TRIX(12,20)
0.071
Sell
StochRSI(14)
30.411
Sell
AstraZeneca PLC
AZN93.220USD
-2.380-2.49%
Close 01/28, 16:00（ET）Quotes delayed by 15 min
289.11BMarket Cap
30.75P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of AstraZeneca PLC
Currency: USD Updated: 2026-01-28Key Insights
AstraZeneca PLC's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 26 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 115.85.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
AstraZeneca PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
AstraZeneca PLC Highlights
StrengthsRisks
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology firm headquartered at the Cambridge Biomedical Campus in Cambridge, UK. The company boasts a diverse portfolio of products aimed at treating major diseases in areas such as oncology, cardiovascular health, gastrointestinal issues, infections, neuroscience, respiratory conditions, and inflammation.
Founded in 1999 through the merger of Swedish Astra AB and British Zeneca Group, it includes offerings for both primary and specialty care, coverage for rare diseases, and maintains a strong global presence across various regions. Since the merger, AstraZeneca has consistently ranked among the largest pharmaceutical companies worldwide and has executed numerous corporate acquisitions, such as Cambridge Antibody Technology, MedImmune, Spirogen, and Definiens. Its research and development efforts are concentrated in three strategic centers: Cambridge in the UK, Gothenburg in Sweden, and Gaithersburg in Maryland, US.
AstraZeneca’s corporate lineage can be traced back to 1913, when Astra AB was established by a significant group of physicians and pharmacists in Södertälje. Throughout the 20th century, Astra AB evolved into Sweden's largest pharmaceutical company. Its British counterpart, Zeneca PLC, was created in 1993 when ICI divested its pharmaceuticals division; six years later, Astra AB and Zeneca PLC merged, designating the United Kingdom as the headquarters.
AstraZeneca's primary listing is on the London Stock Exchange, where it is part of the FTSE 100 Index, alongside a secondary listing on Nasdaq Stockholm. It is also traded on the American Nasdaq and is included in the Nasdaq-100 index. AstraZeneca ranks among the pharmaceutical companies globally with one of the highest market capitalizations.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 21.92% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 54.07B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 68.32%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 68.32%.
Undervalued
The company’s latest PE is 30.75, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 518.15M shares, increasing 0.38% quarter-over-quarter.
Held by Brandes Investmen
Star Investor Brandes Investmen holds 1.04K shares of this stock.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
115.848
Target Price
+24.64%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-01-28The current financial score of AstraZeneca PLC is 8.92, ranking 27 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 15.19B, representing a year-over-year increase of 11.99%, while its net profit experienced a year-over-year increase of 77.26%.
Score
Financials
6.42
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
9.42
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
8.74
AstraZeneca PLC's Company Valuation
Currency: USD Updated: 2026-01-28The current valuation score of AstraZeneca PLC is 8.13, ranking 31 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 30.75, which is 119.28% below the recent high of 67.42 and 16.44% above the recent low of 25.69.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 26/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-01-28The current earnings forecast score of AstraZeneca PLC is 8.67, ranking 12 out of 159 in the Pharmaceuticals industry. The average price target is 99.00, with a high of 232.41 and a low of 67.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
115.848
Target Price
+24.64%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
173
Total
6
Median
8
Average
Company name
Ratings
Analysts
AstraZeneca PLC
AZN
12
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
Gilead Sciences Inc
GILD
31
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-01-28The current price momentum score of AstraZeneca PLC is 7.46, ranking 44 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 96.81 and the support level at 89.34, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
93.538
Sell
MA10
93.289
Sell
MA20
93.352
Sell
MA50
91.907
Buy
MA100
86.945
Buy
MA200
79.666
Buy
Institutional Confidence
Currency: USD Updated: 2026-01-28The current institutional shareholding score of AstraZeneca PLC is 3.00, ranking 94 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 17.29%, representing a quarter-over-quarter decrease of 0.27%. The largest institutional shareholder is PRIMECAP Management, holding a total of 39.86M shares, representing 1.28% of shares outstanding, with 1.99% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Wellington Management Company, LLP
T. Rowe Price International Ltd
Capital International Investors
Managed Account Advisors LLC
Fidelity Management & Research Company LLC
Sanders Capital, LLC
Putnam Investment Management, L.L.C.
1
2
Risk Assessment
Currency: USD Updated: 2026-01-28The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of AstraZeneca PLC is 9.88, ranking 3 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.35. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.35
VaR
+2.39%
240-Day Maximum Drawdown
+16.79%
240-Day Volatility
+25.17%
Return
Best Daily Return
60 days
+4.10%
120 days
+9.96%
5 years
+9.96%
Worst Daily Return
60 days
-4.71%
120 days
-4.71%
5 years
-8.83%
Sharpe Ratio
60 days
+2.72
120 days
+2.16
5 years
+0.75
Risk Assessment
Maximum Drawdown
240 days
+16.79%
3 years
+27.87%
5 years
+27.87%
Return-to-Drawdown Ratio
240 days
+1.87
3 years
+0.56
5 years
+0.63
Skewness
240 days
+0.38
3 years
-0.36
5 years
-0.20
Volatility
Realised Volatility
240 days
+25.17%
5 years
+24.69%
Standardised True Range
240 days
+1.60%
5 years
+1.31%
Downside Risk-Adjusted Return
120 days
+413.88%
240 days
+413.88%
Maximum Daily Upside Volatility
60 days
+20.13%
Maximum Daily Downside Volatility
60 days
+19.25%
Liquidity
Average Turnover Rate
60 days
+0.28%
120 days
+0.32%
5 years
--
Turnover Deviation
20 days
-30.14%
60 days
-17.54%
120 days
-5.43%
Peer Comparison
Pharmaceuticals
AstraZeneca PLC
AZN
7.96 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
8.94 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.89 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.79 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Kiniksa Pharmaceuticals International PLC
KNSA
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
